Healthcare IT · Regulatory compliance software
Enzyme
Cloud quality management software built so small life science companies could survive an FDA inspection without hiring a consulting firm. Acquired in July 2025 by the largest company in its own category. Its chief executive now runs technology policy at the FDA.
Four logins before the work started
Jacob Graham spent more than a decade inside the two largest medical device manufacturers in the world, at Boston Scientific and then Medtronic, in design assurance and quality systems. The job came with a daily ritual that had nothing to do with devices.
“After working for the two largest medical device manufacturers, I saw that while they had created very different quality systems, they both used a wide variety of tools for their workflows,” he told his alma mater, Olin College, in 2023. Training in one platform. Performance in a second. Compliance in a third. “I knew there had to be a more streamlined way.”
In 2016 a friend called with an idea: collapse all of it into one cloud application. The friend was Jared Seehafer, a biomedical engineer who had led spinal cord stimulator programs at St. Jude Neuromodulation and worked on the interface for Medtronic’s first hybrid closed loop insulin pump. In 2017, by Graham’s account, the idea launched as Enzyme.
The documentation tax
Anyone selling a drug, a diagnostic or a device in the United States must show the FDA the product is safe and effective, then keep showing it for as long as the product is sold, in records an investigator can demand at any time.
“You find you spend almost as much time documenting the work as you do doing the work,” Seehafer told TechCrunch in January 2018. Rock Health, which invested that month, wrote that small device, drug or digital health companies “can shell out hundreds of thousands of dollars annually in consulting fees on labor-intensive, slow, paper-based processes”.
An engineer and a quality manager
The founders split the problem along their own careers. Seehafer took the regulatory side: combination product submissions for Amgen products including Neulasta Onpro and Repatha Pushtronex, later the combination product practice at Suttons Creek. Graham took the quality side, an ASQ Certified Biomedical Auditor who had carried Class II and Class III devices through FDA and notified body audits.
Enzyme ran its own quality system inside the product it sold, the strongest thing a compliance vendor can say about itself. “we use Enzyme to document our own QMS,” Graham said in 2023.
Sold to the company ranked first
On July 23, 2025, Greenlight Guru announced it had bought Enzyme. The buyer is the category leader by every available count: Tracxn ranks it first among 150 competitors at $121 million raised, against Enzyme’s $1.97 million and a rank of twentieth, and the release says it serves more than 1,100 medical device companies with backing from JMI Equity. Terms were not disclosed. It was the second deal in five weeks, after Ultralight Labs in June.
The trigger was personal. Both the release and Seehafer’s farewell note say the sale followed his decision to leave. “Enzyme achieved a great deal, but ensuring that we meet the evolving needs of customers requires a more mature infrastructure,” he wrote, closing with a tease: “I’ve been offered an opportunity to continue this mission from the other side of the table, so to speak”.
The other side of the table turned out to be the regulator. Seehafer joined the FDA in August 2025 as a senior advisor in the Office of Policy, Legislation, and International Affairs. In September 2026 the Department of Health and Human Services named him the agency’s first Deputy Commissioner for Technology and Artificial Intelligence. The founder who sold software to help companies survive FDA inspections now sets FDA technology strategy.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Named customer | Lucira Health filed a Form 8-K on Apr 18, 2023 attaching its asset purchase agreement with Pfizer Inc. Schedule 1.1(e), Assigned Contracts, lists Enzyme Corporation, description Service Agreement. Lucira made the first FDA-authorized at-home molecular COVID-19 test, and the contract was one of roughly 25 carried into the Pfizer sale. | Public record |
| Early customers | Rock Health, an investor, wrote in January 2018 that the product was in use at 10 device and diagnostic companies, naming PathAI and Biomeme. No customer list was ever published. | Investor |
| Founder to regulator | FDA’s leadership page states Seehafer joined in 2025 and is its first Deputy Commissioner for Technology and Artificial Intelligence. CNBC reported the plan on Aug 25, 2026. | Public record |
| Enzyme’s certification | The website states a commitment to applicable ISO 9001:2015 requirements, which is a policy, not a certificate. No ISO 13485 registration, SOC 2 report or third party attestation for Enzyme itself was found. | Not found |
| Product claims | 21 CFR Part 11 compliant, validated out of the box, 12 modules, Jira and GitHub integrations, Okta single sign-on listed since April 2019. No validation package is public. | Company-stated |
| Revenue and customers | GetLatka estimates $10.3M of 2024 revenue and reports 21 customers at an average $488,600. The 21 is the number Seehafer gave in December 2018, when he put the run rate near $1M and the sweet spot near $50,000 a year. | Differs from the founder record |
| Ownership before the sale | Olin College reported in March 2023 that Roivant Sciences became majority shareholder in 2022. Roivant appears in no acquisition coverage, investor list or SEC filing about this company. | Single source |
| Securities filings | No Form D was ever filed under Enzyme Corporation. An EDGAR search for Form D filers named enzyme returns only EnzymeBioSystems, Enzyme Media and Wheel Health. | Not found |
Read plainly: a real business with real customers, one provable from a bankruptcy exhibit rather than a marketing page, sold to the market leader after eight years on roughly two million dollars. What it never published is the thing its own customers must produce: an independent audit of its quality and security posture. For a vendor holding the design history files FDA investigators read, that absence is the loudest fact on the page.
What to watch
- Whether Enzyme customers are migrated onto the Greenlight Guru platform or kept on a separate product.
- The FDA Quality Management System Regulation, effective February 2, 2026, which folds ISO 13485:2016 into 21 CFR Part 820 and ends the old exclusion of management reviews and internal and supplier audit reports from inspection.
- Consolidation. Greenlight Guru bought Ultralight Labs and Enzyme in five weeks. Qualio, MasterControl and Ketryx remain independent.
- Seehafer’s posture at the FDA on software and AI, after eight years selling compliance tooling to the companies the agency inspects.
In their words
“You find you spend almost as much time documenting the work as you do doing the work.”
Jared Seehafer, co-founder and CEO, to TechCrunch, January 2018 · Independent
“After working for the two largest medical device manufacturers, I saw that while they had created very different quality systems, they both used a wide variety of tools for their workflows.”
Jacob Graham, co-founder and COO, Olin College, March 2023 · Independent
“With Enzyme, some of our customers have cut the time between code completion and deployment to users from eight weeks to two weeks.”
Jacob Graham, Olin College, March 2023 · Independent
“Ultimately a company will succeed when everyone understands and contributes to the quality culture.”
Jacob Graham, company interview, February 2019 · Company
“Enzyme achieved a great deal, but ensuring that we meet the evolving needs of customers requires a more mature infrastructure.”
Jared Seehafer, farewell post, July 2025 · Company
“These moves not only further consolidate the competitive landscape but also enhance our differentiation with expanded integrations, and greater flexibility.”
Ed Holmes, CEO, Greenlight Guru, acquisition release, July 24, 2025 · Acquirer release
“Jared Seehafer is FDA’s first Deputy Commissioner for Technology and Artificial Intelligence.”
FDA leadership page, September 2026 · Public record
Related companies
Sources
- Public recordLucira Health Form 8-K, Exhibit 2.1, asset purchase agreement with Pfizer Inc.
- Public recordJared Seehafer, Deputy Commissioner for Technology and AI
- Public recordQuality Management System Regulation
- Public recordQuality System Regulation Amendments, final rule
- Public recordEDGAR company and full text searches for Enzyme Corporation
- Public record510(k)s K896073 to K912028, Enzyme Technology, Inc.
- IndependentEnzyme.com wants to make FDA compliance easier for startups
- IndependentAlum’s startup becomes big player in biomedical and software industries
- IndependentHHS plans new FDA deputy commissioner roles
- IndependentSeehafer named FDA deputy commissioner for tech and AI
- IndependentGreenlight Guru acquires Enzyme, deal record
- IndependentA QMSR state of mind: FDA adopts new inspection approach
- IndependentEnzyme profile, funding and competitors
- IndependentEnzyme reviews, ratings and pricing
- IndependentEnzyme estimates and 2018 founder interview transcript
- InvestorFDA compliance made easy: welcome, Enzyme
- AcquirerGreenlight Guru acquires Enzyme
- CompanyA grateful goodbye and a confident step forward
- CompanyAbout, founder, product and security pages
- CompanyCreating a culture of quality, interview with Jacob Graham
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
